CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
0.357
0%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.021
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.020734 %
Charges from full value of position ($-3.94)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.020734%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.001184 %
Charges from full value of position ($-0.22)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.001184%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency SGD
Margin 5%
Stock exchange Singapore
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 0.357
Open* 0.357
1-Year Change* -12.29%
Day's Range* 0.357 - 0.357
52 wk Range 0.37-0.44
Average Volume (10 days) 20.49K
Average Volume (3 months) 194.33K
Market Cap 497.07M
P/E Ratio 15.26
Shares Outstanding 1.33B
Revenue 81.93M
EPS 0.02
Dividend (Yield %) 6.4
Beta 0.19
Next Earnings Date Feb 22, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 28, 2024 0.357 0.000 0.00% 0.357 0.357 0.357
Mar 27, 2024 0.357 0.000 0.00% 0.357 0.357 0.357
Mar 26, 2024 0.357 -0.005 -1.38% 0.362 0.362 0.357
Mar 25, 2024 0.362 0.000 0.00% 0.362 0.362 0.362
Mar 21, 2024 0.362 -0.005 -1.36% 0.367 0.367 0.357
Mar 19, 2024 0.357 0.000 0.00% 0.357 0.362 0.357
Mar 18, 2024 0.362 0.000 0.00% 0.362 0.362 0.362
Mar 15, 2024 0.362 0.000 0.00% 0.362 0.362 0.362
Mar 14, 2024 0.362 0.000 0.00% 0.362 0.362 0.362
Mar 13, 2024 0.362 0.000 0.00% 0.362 0.367 0.362
Mar 12, 2024 0.362 0.000 0.00% 0.362 0.362 0.362
Mar 11, 2024 0.362 -0.005 -1.36% 0.367 0.367 0.362
Mar 8, 2024 0.367 0.005 1.38% 0.362 0.367 0.362
Mar 7, 2024 0.362 0.000 0.00% 0.362 0.362 0.362
Mar 6, 2024 0.362 0.000 0.00% 0.362 0.362 0.362
Mar 5, 2024 0.362 0.000 0.00% 0.362 0.362 0.362
Mar 1, 2024 0.362 0.000 0.00% 0.362 0.362 0.362
Feb 29, 2024 0.372 0.000 0.00% 0.372 0.372 0.372
Feb 28, 2024 0.367 0.000 0.00% 0.367 0.367 0.367
Feb 27, 2024 0.367 -0.005 -1.34% 0.372 0.372 0.367

$ TalkMed Events

Time (UTC) Country Event
Friday, April 19, 2024

Time (UTC)

10:00

Country

SG

Event

Talkmed Group Ltd Annual Shareholders Meeting
Talkmed Group Ltd Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 76.6 60.746 62.136 75.919 61.278
Revenue 76.6 60.746 62.136 75.919 61.278
Total Operating Expense 37.498 32.385 36.244 33.52 26.138
Selling/General/Admin. Expenses, Total 29.994 26.604 26.536 25.402 22.909
Interest Expense (Income) - Net Operating -0.672 -0.114 -0.472 -1.185 -0.982
Other Operating Expenses, Total 4.993 4.718 4.766 5.878 4.211
Operating Income 39.102 28.361 25.892 42.399 35.14
Net Income Before Taxes 36.847 27.286 24.807 41.349 34.003
Net Income After Taxes 28.991 21.428 18.517 32.806 27.214
Minority Interest 1.556 3.687 4.252 2.945 1.694
Net Income Before Extra. Items 30.547 25.115 22.769 35.751 28.908
Net Income 30.547 25.115 22.769 35.751 28.908
Income Available to Common Excl. Extra. Items 30.547 25.115 22.769 35.751 28.908
Income Available to Common Incl. Extra. Items 30.547 25.115 22.769 35.751 28.908
Diluted Net Income 30.547 25.115 22.769 35.751 28.908
Diluted Weighted Average Shares 1329.49 1326.99 1324.25 1314.72 1314.8
Diluted EPS Excluding Extraordinary Items 0.02298 0.01893 0.01719 0.02719 0.02199
Dividends per Share - Common Stock Primary Issue 0.03 0.016 0.0135 0.023 0.01826
Diluted Normalized EPS 0.02336 0.01815 0.01827 0.02719 0.02199
Interest Income (Expense), Net Non-Operating -2.255 -1.075 -1.085 -1.05 -1.137
Depreciation / Amortization 2.543 2.488 3.513 3.425
Unusual Expense (Income) 0.64 -1.311 1.901
Jun 2023 Dec 2022 Jun 2022 Dec 2021 Jun 2021
Total revenue 37.795 44.131 32.469 31.892 28.854
Revenue 37.795 44.131 32.469 31.892 28.854
Total Operating Expense 20.379 20.514 16.984 16.414 15.971
Selling/General/Admin. Expenses, Total 15.624 16.341 13.653 13.987 12.617
Depreciation / Amortization 1.366 1.265 1.278 1.289 1.199
Interest Expense (Income) - Net Operating -0.893 -0.638 -0.034 -0.095 -0.019
Other Operating Expenses, Total 3.828 2.906 2.087 1.233 2.174
Operating Income 17.416 23.617 15.485 15.478 12.883
Interest Income (Expense), Net Non-Operating -1.003 -1.386 -0.869 -0.719 -0.356
Net Income Before Taxes 16.413 22.231 14.616 14.759 12.527
Net Income After Taxes 12.489 17.542 11.449 11.694 9.734
Minority Interest 1.783 0.875 0.681 2.611 1.076
Net Income Before Extra. Items 14.272 18.417 12.13 14.305 10.81
Net Income 14.272 18.417 12.13 14.305 10.81
Income Available to Common Excl. Extra. Items 14.272 18.417 12.13 14.305 10.81
Income Available to Common Incl. Extra. Items 14.272 18.417 12.13 14.305 10.81
Diluted Net Income 14.272 18.417 12.13 14.305 10.81
Diluted Weighted Average Shares 1331.55 1330.02 1328.96 1327.46 1326.52
Diluted EPS Excluding Extraordinary Items 0.01072 0.01385 0.00913 0.01078 0.00815
Dividends per Share - Common Stock Primary Issue 0.009 0.015 0.015 0.009 0.007
Diluted Normalized EPS 0.01098 0.01423 0.00913 0.01078 0.00815
Unusual Expense (Income) 0.454 0.64 0
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 94.782 92.424 91.313 94.431 83.637
Cash and Short Term Investments 81.241 82.164 79.43 80.698 73.993
Cash 22.494 15.258 10.132 18.373 13.421
Short Term Investments 58.747 66.906 69.298 62.325 60.572
Total Receivables, Net 11.822 9.002 10.295 12.267 8.714
Accounts Receivable - Trade, Net 11.016 8.365 9.503 11.422 8.307
Total Inventory 1.275 0.772 1.004 0.856 0.282
Prepaid Expenses 0.444 0.486 0.584 0.61 0.648
Total Assets 109.166 108.785 104.62 106.075 91.272
Property/Plant/Equipment, Total - Net 10.082 8.514 6.172 8.739 4.227
Property/Plant/Equipment, Total - Gross 17.163 15.135 13.724 11.461 5.485
Accumulated Depreciation, Total -7.081 -6.621 -7.552 -2.722 -1.258
Long Term Investments 3.696 7.437 7.11 2.887 3.404
Note Receivable - Long Term 0.606 0.41
Total Current Liabilities 19.383 14.245 17.411 16.768 12.735
Accounts Payable 0.804 0.628 0.402 1.284 0.522
Accrued Expenses 4.684 3.397 4.152 3.353 3.935
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 12.044 8.245 11.071 10.357 8.278
Total Liabilities 20.452 18.607 21.186 22.97 17.506
Total Long Term Debt 2.552 4.493 2.69 2.119 0
Minority Interest -4.165 -2.678 -4.679 -1.414 -0.415
Other Liabilities, Total 2.682 2.547 5.764 5.497 5.186
Total Equity 88.714 90.178 83.434 83.105 73.766
Common Stock 25.119 24.505 23.905 22.438 22.273
Retained Earnings (Accumulated Deficit) 63.743 65.109 59.316 60.957 51.988
Total Liabilities & Shareholders’ Equity 109.166 108.785 104.62 106.075 91.272
Total Common Shares Outstanding 1322.55 1320.11 1318.05 1314.5 1314.29
Other Long Term Assets, Total 0 0.025 0.018 0.004
Other Equity, Total -0.148 0.564 0.213 -0.29 -0.495
Current Port. of LT Debt/Capital Leases 1.851 1.975 1.786 1.774
Capital Lease Obligations 2.552 4.493 2.69 2.119
Jun 2023 Dec 2022 Jun 2022 Dec 2021 Jun 2021
Total Current Assets 92.43 94.782 93.873 92.424 89.516
Cash and Short Term Investments 81.588 81.241 83.746 82.164 80.945
Cash & Equivalents 81.074 80.588 83.746 82.164 80.945
Total Receivables, Net 9.323 11.822 8.745 9.002 7.064
Accounts Receivable - Trade, Net 9.323 11.822 8.745 9.002 7.064
Total Inventory 1.208 1.275 0.927 0.772 1.047
Prepaid Expenses 0.311 0.444 0.455 0.486 0.46
Total Assets 105.776 109.166 108.024 108.785 101.839
Property/Plant/Equipment, Total - Net 10.277 10.082 7.252 8.514 5.394
Long Term Investments 2.693 3.696 6.654 7.437 6.892
Other Long Term Assets, Total 0 0.037
Total Current Liabilities 23.023 19.383 14.617 14.245 13.015
Accounts Payable 4.538 2.867 2.253 2.17 2.204
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 1.876 1.851 2.001 1.975 1.161
Other Current Liabilities, Total 16.609 14.665 10.363 10.1 9.65
Total Liabilities 22.47 20.452 17.423 18.607 17.044
Total Long Term Debt 2.619 2.552 3.514 4.493 2.244
Capital Lease Obligations 2.619 2.552 3.514 4.493 2.244
Minority Interest -5.913 -4.165 -3.323 -2.678 -0.829
Other Liabilities, Total 2.741 2.682 2.615 2.547 2.614
Total Equity 83.306 88.714 90.601 90.178 84.795
Common Stock 25.572 25.119 24.997 24.505 24.505
Retained Earnings (Accumulated Deficit) 57.934 63.743 65.074 65.109 59.865
Other Equity, Total -0.2 -0.148 0.53 0.564 0.425
Total Liabilities & Shareholders’ Equity 105.776 109.166 108.024 108.785 101.839
Total Common Shares Outstanding 1324.5 1322.55 1322.05 1320.11 1320.11
Note Receivable - Long Term 0.376 0.606 0.245 0.41
Short Term Investments 0.514 0.653
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line 36.847 27.286 24.807 41.349 34.003
Cash From Operating Activities 37.291 23.158 31.273 35.883 30.079
Cash From Operating Activities 2.543 2.488 3.513 3.425 0.376
Non-Cash Items 2.999 0.776 6.316 0.272 0.819
Cash Taxes Paid 5.888 9.101 5.713 6.77 7.34
Changes in Working Capital -5.098 -7.392 -3.363 -9.163 -5.119
Cash From Investing Activities -5.012 -1.977 -8.446 -2.003 -3.929
Capital Expenditures -4.326 -0.77 -1.954 -2.128 -3.929
Other Investing Cash Flow Items, Total -0.686 -1.207 -6.492 0.125
Cash From Financing Activities -33.855 -18.447 -24.095 -27.175 -23.208
Financing Cash Flow Items 0 2.8 2.51 1.883 4.8
Total Cash Dividends Paid -31.729 -19.141 -25.042 -27.142 -28.008
Net Change in Cash -1.576 2.734 -1.268 6.705 2.942
Cash Interest Paid 0.211 0.219 0.237 0.122
Issuance (Retirement) of Debt, Net -2.126 -2.106 -1.563 -1.916
Dec 2022 Jun 2022 Dec 2021 Jun 2021 Dec 2020
Net income/Starting Line 36.847 14.616 27.286 12.527 24.807
Cash From Operating Activities 37.291 14.574 23.158 11.307 31.273
Cash From Operating Activities 2.543 1.278 2.488 1.199 3.513
Non-Cash Items 2.999 1.169 0.776 0.802 6.316
Cash Taxes Paid 5.888 2.944 9.101 5.962 5.713
Cash Interest Paid 0.211 0.114 0.219 0.119 0.237
Changes in Working Capital -5.098 -2.489 -7.392 -3.221 -3.363
Cash From Investing Activities -5.012 -0.109 -1.977 -0.398 -8.446
Capital Expenditures -4.326 -0.023 -0.77 -0.398 -1.954
Other Investing Cash Flow Items, Total -0.686 -0.086 -1.207 -6.492
Cash From Financing Activities -33.855 -119.966 -18.447 -9.394 -24.095
Total Cash Dividends Paid -31.729 -118.981 -19.141 -9.9 -25.042
Issuance (Retirement) of Debt, Net -2.126 -0.985 -2.106 -1.094 -1.563
Net Change in Cash -1.576 1.582 2.734 1.515 -1.268
Financing Cash Flow Items 0 0 2.8 1.6 2.51

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

TalkMed Company profile

About TalkMed Group Ltd

TalkMed Group Limited is a Singapore-based investment holding company. The Company’s Oncology services segment is engaged in the provision of oncology services to Parkway Cancer Centre, a division of Parkway Hospitals Singapore Pte. Ltd., Thu Cuc International General Hospital in Hanoi, Vietnam and Hong Kong Integrated Oncology Centre Holdings Limited. The Company has expanded its oncology services to China. Its Stem cell related products and services segment is engaged in the provision of services related to processing, culturing and storage of stem cells through its subsidiary, Stem Med Pte. Ltd. (Stem Med) to Parkway Cancer Centre, a division of Parkway Hospitals Singapore Pte. Ltd., StemCord Pte Ltd, the non-controlling shareholder of Stem Med and other individual customers. The Cellular and gene therapy related products and services segment is engaged in the provision of goods and services related to cellular and gene therapy through its subsidiary, CellVec Pte. Ltd.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, TalkMed Group Ltd revenues decreased 2% to SP$60.7M. Net income increased 10% to SP$25.1M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net income reflects Impairment loss decrease from SP$3.4M (expense) to SP$0K, Cost of share-based payments to employee decrease of 76% to SP$512K (expense).

Industry: Healthcare Facilities & Services (NEC)

101 Thomson Road
#09-02 United Square
307591
SG

Income Statement

  • Annual
  • Quarterly

News

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

Four reasons why Bitcoin is surging to record highs

Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.

10:18, 14 March 2024

China’s National People’s Congress: The markets have again been left wanting more

China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.

08:23, 8 March 2024
Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

13:14, 6 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

People also watch

XRP/USD

0.64 Price
+3.240% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

Gold

2,218.08 Price
+1.050% 1D Chg, %
Long position overnight fee -0.0188%
Short position overnight fee 0.0106%
Overnight fee time 21:00 (UTC)
Spread 0.30

BTC/USD

70,659.20 Price
+2.540% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

US100

18,236.90 Price
-0.240% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading